Wal-Mart Woes Slow ...
Health Care: Drugs
Gilead Sciences Inc (GILD: NASDAQ)
$56.30 1.34 | 2.44%
05/17/13 - 04:00 PM ET
Portfolios with GILD
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- UserDC
- ProHighbridge Capital Management
- ProSteven Cohen - SAC Capital
- ProJohn Griffin - Blue Ridge C...
- UserMike Fatah's Mega Stock Por...
- UserRenzo's portfolio
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 23
- UserBender
Latest GILD Headlines from TheStreet
- Quick Take: The Next Big Thing in Biotech 05.17.13 | 10:05 am
- 'Mad Money' Lightning Round: Magnum Hunter Blew It 05.17.13 | 06:05 am
- Biotech's Next Big Thing ASCO II
05.16.13 | 02:05 pm - ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up 05.15.13 | 06:05 pm
- ASCO '13 Preview: Gilead's Big Cancer Debut 05.15.13 | 06:05 pm
- 5 Stocks Boosting The Drugs Industry Higher 05.15.13 | 01:05 pm
- Gilead Reaches New 52-Week High (GILD) 05.15.13 | 09:05 am
- Gilead Sciences Inc (GILD): Today's Featured Health Care Winner 05.13.13 | 05:05 pm
- Cramer: Biotech Makes a Comeback 05.10.13 | 04:05 pm
- Biotech's Next Big Thing: ASCO 05.09.13 | 09:05 am
Press Releases for GILD
- Gilead Announces Update On Phase 3 Study Of Oral Fixed-Dose Combination Of Sofosbuvir And Ledipasvir For Genotype 1 Hepatitis C Patients - Business Wire 03.26.13 | 08:03 am
- European CHMP Adopts Positive Opinion For Stribild®, A Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen For The Treatment Of HIV-1 Infection - Business Wire 03.22.13 | 08:03 am
- Gilead’s Ranexa® Reduces Angina Frequency In Study Of Chronic Angina Patients With Type 2 Diabetes - Business Wire 03.10.13 | 02:03 pm
- Gilead Announces Full 24-Week Phase 2 Results For Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF) - Business Wire 03.05.13 | 12:03 pm
- Gilead Sciences To Present At The Cowen & Company 33rd Annual Health Care Conference On Monday, March 4 - Business Wire 03.01.13 | 04:03 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.25.13 | 04:02 pm
- Gilead And Teva Reach Settlement Agreement In Viread® Patent Litigation - Business Wire 02.19.13 | 11:02 pm
- Gilead’s Sofosbuvir For Hepatitis C Meets Primary Endpoint In Fourth Pivotal Phase 3 Study - Business Wire 02.19.13 | 08:02 am
- Gilead Issues A Voluntary Recall Of One Lot Of Vistide® (Cidofovir Injection) Due To Presence Of Particulate Matter - Business Wire 02.15.13 | 06:02 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.11.13 | 04:02 pm
Partner Headlines for GILD
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Dow, S&P 500 Flirt With All-Time Highs; Asset Managers Continue Outperformance - Investor's Business Daily 04.09.13 | 05:04 pm
- Buyers Put Money To Work; Dow, S&P 500 Touch Highs - Investor's Business Daily 04.09.13 | 04:04 pm
- Stocks Flat As Early Gains Fade; Regeneron Hits New High - Investor's Business Daily 04.09.13 | 10:04 am
- Some Companies Aren't Evil... And Some Even Save Lives - Benzinga 04.05.13 | 09:04 am
- U.S. Mutual Funds Up 10% In Q1; Managers' Top Buys - Investor's Business Daily 04.02.13 | 06:04 pm
- DFC Global Lowers Outlook and 2 Other Stocks At 52-Week Lows - Wall St. Cheat Sheet 04.02.13 | 09:04 am
- After Hours Most Active for Apr 1, 2013 : BAC, FCX, QQQ, CPNO, PNG, INTC, VCSH, HUM, GILD, MS, VCIT, AER - NASDAQ 04.01.13 | 08:04 pm
- Analysts: Dell Earnings May Get Pressured and 4 New Opinions Investors Must Take a Peek At - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Analysts: Dell Earnings May Get Pressured and 4 New Opinions Investors Must Take a Peek At - Wall St. Cheat Sheet 04.01.13 | 11:04 am
